CHAMPS clinical trial
Jump to navigation
Jump to search
Introduction
A clinical trial finding that betaseron (interferon-beta 1b) reduced the conversion from early possible multiple sclerosis (MS) to definite MS.
More general terms
Additional terms
- interferon [IFN]-beta 1B (betaseron, Extavia)
- multiple sclerosis (MS); includes clinically isolated syndrome